Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis

Lung Cancer

Volumn 65, Issue 2, 2009, Pages 237-241

  Di Bernardo, Maria Chiara ^a   Matakidou, Athena ^a   Eisen, Tim ^b   Houlston, Richard S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Lung cancer; Plasminogen; Polymorphism; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2;

ADULT; ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; GENOTYPE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PLASMINOGEN ACTIVATORS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SMALL CELL LUNG CARCINOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 67449156434     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.11.012     Document Type: Article

References (16)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Andreasen P.A., Egelund R., and Petersen H.H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57 (2000) 25-40
3. Nordengren J., Fredstorp Lidebring M., Bendahl P.O., Brunner N., Ferno M., Hogberg T., et al. High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer. Int J Cancer 97 (2002) 379-385
4. Yoshino H., Endo Y., Watanabe Y., and Sasaki T. Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis. Br J Cancer 78 (1998) 833-839
5. Schmitt M., Harbeck N., Thomssen C., Wilhelm O., Magdolen V., Reuning U., et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 78 (1997) 285-296
6. Duffy M.J., Reilly D., O'Sullivan C., O'Higgins N., Fennelly J.J., and Andreasen P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50 (1990) 6827-6829
7. Ganesh S., Sier C.F., Griffioen G., Vloedgraven H.J., de Boer A., Welvaart K., et al. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 54 (1994) 4065-4071
8. Chambers S.K., Gertz Jr. R.E., Ivins C.M., and Kacinski B.M. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer. Cancer 75 (1995) 1627-1633
9. Matakidou A., Eisen T., Bridle H., O'Brien M., Mutch R., and Houlston R.S. Case-control study of familial lung cancer risks in UK women. Int J Cancer 116 (2005) 445-450
10. Jemal A., Thomas A., Murray T., and Thun M. Cancer statistics, 2002. CA Cancer J Clin 52 (2002) 23-47
11. Werle B., Kotzsch M., Lah T.T., Kos J., Gabrijelcic-Geiger D., Spiess E., et al. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. Anticancer Res 24 (2004) 4147-4161
12. Yoshimoto A., Kasahara K., Kawashima A., Fujimura M., and Nakao S. Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: a comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases. Oncol Rep 13 (2005) 1049-1057
13. Esposito V., Groeger A.M., De Luca L., Di Marino M., Santini D., Marchei P., et al. Expression of surface protein receptors in lung cancer. Anticancer Res 22 (2002) 4039-4043
14. Lei H., Hemminki K., Johansson R., Altieri A., Enquist K., Henriksson R., et al. PAI-1-675 4G/5G polymorphism as a prognostic biomarker in breast cancer. Breast Cancer Res Treat 109 (2008) 165-175
15. Forsti A., Lei H., Tavelin B., Enquist K., Palmqvist R., Altieri A., et al. Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer. Ann Oncol 18 (2007) 1990-1994
16. Zhang X., Shu X.O., Cai Q., Ruan Z., Gao Y.T., and Zheng W. Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival. Clin Cancer Res 12 (2006) 6037-6042